{
    "clinical_study": {
        "@rank": "47004", 
        "acronym": "GWPCI", 
        "biospec_descr": {
            "textblock": "CBC, Electrolyte, Chemistry, Cardiac biomarker, Platelet function test"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Comparison of\n\n        -  Biolimus-eluting stent, Biomatrix, or Biomatrix Flex stent, Biosensors, Singapore\n\n        -  Everolimus-eluting stent, Xience V, or Xience Prime, or Xience Xpedition stent, Abbott,\n           USA\n\n        -  Zotarolimus-eluting stent, Endeavor Resolute, or Endeavor Resolute Integrity stent\n           Medtronic, USA in patients with coronary artery disease treated with percutaneous\n           coronary intervention"
        }, 
        "brief_title": "Gangwon PCI Registry", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 19 years\n\n          -  Subject is able to verbally confirm understanding of risks, benefits and treatment\n             alternatives of receiving the drug-eluting stent(s) and he/she or his/her legally\n             authorized representative provides written informed consent prior to any study\n             related procedure\n\n          -  Subject must have significant stenosis (>50% by visual estimate) on a native or\n             in-stent coronary artery\n\n          -  Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,\n             recent infarction, acute myocardial infarction, positive functional study or a\n             reversible changes in the ECG consistent with ischemia). In subjects with coronary\n             artery stenosis >75%, evidence of myocardial ischemia does not have to be documented\n\n        Exclusion Criteria:\n\n          -  Subject has a known hypersensitivity or contraindication to any of the following\n             medications: heparin, aspirin, clopidogrel, prasugrel, ticagrelor, biolimus A9,\n             everolimus, zotarolimus, stainless steel, cobalt chromium, contrast media (Patients\n             with documented sensitivity to contrast media, which can be effectively premedicated\n             with steroid and diphenhydramine may be enrolled. However, those with true\n             anaphylaxis to prior contrast media should not be enrolled.)\n\n          -  Subject in use of systemic (intravenous) biolimus A9, everolimus or zotarolimus\n             within 12 months.\n\n          -  Female subject of childbearing potential, unless a recent pregnancy test is negative,\n             who possibly plans to become pregnant any time after enrollment into this study\n\n          -  Subject planned an elective surgical procedure that would necessitate interruption of\n             antiplatelet during the first 12 months post enrollment\n\n          -  Subject with non-cardiac co-morbid condition with life expectancy < 2 year or that\n             may result in protocol non-compliance (per site investigator's medical judgment)\n\n          -  Subject with cardiogenic shock at presentation\n\n          -  Subject who are actively participating in another drug or device investigational\n             study, who have not completed the primary end point follow-up period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients who were at least 18 years of age, who have stable coronary artery disease (CAD)\n        or acute coronary syndrome (ACS), including myocardial infarction (MI) with or without\n        ST-segment elevation will be included in the study."
            }
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038127", 
            "org_study_id": "GangwonPCI"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jumdure@hanmail.net", 
                    "last_name": "Hyun Hee Choi, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Chuncheon", 
                        "country": "Korea, Republic of", 
                        "state": "Gangwon"
                    }, 
                    "name": "Chuncheon Hallym University Hospital"
                }, 
                "investigator": {
                    "last_name": "Hyun Hee Choi, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jyoon@yonsei.ac.kr", 
                    "last_name": "Junghan Yoon, M.D., Ph.D.", 
                    "phone": "+82-33-741-0906"
                }, 
                "facility": {
                    "address": {
                        "city": "Wonju", 
                        "country": "Korea, Republic of", 
                        "state": "Gangwon", 
                        "zip": "220768"
                    }, 
                    "name": "Yonsei University Wonju Christian Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Young Jin Youn, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Junghan Yoon, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Seung-Hwan Lee, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sung-Gyun Ahn, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jun-Won Lee, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wmagpie@korea.com", 
                    "last_name": "Cheol Ung Choi, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Guro Hospital"
                }, 
                "investigator": {
                    "last_name": "Cheol Ung Choi, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Registry for Patients Undergoing Coronary Angiography and Percutaneous Coronary Intervention in Gangwon Province", 
        "overall_contact": {
            "email": "jyoon@yonsei.ac.kr", 
            "last_name": "Junghan Yoon, M.D., Ph.D.", 
            "phone": "+82-33-741-0906"
        }, 
        "overall_contact_backup": {
            "email": "younyj@yonsei.ac.kr", 
            "last_name": "Young Jin Youn, M.D.", 
            "phone": "+82-33-741-0917"
        }, 
        "overall_official": {
            "affiliation": "Yonsei University", 
            "last_name": "Junghan Yoon, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Device-oriented composite consisted of cardiac death, MI not clearly attributable to a nontarget vessel, and clinically indicated TLR at 24-month clinical follow-up", 
            "measure": "Device-oriented composite outcome", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038127"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yonsei University", 
            "investigator_full_name": "Yoon Junghan", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Patient-oriented composite consisted of all-cause mortality, any MI, and any revascularization at 24-month clinical follow-up", 
                "measure": "Patient-oriented composite outcome", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Target vessel revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Target vessel revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "ARC defined stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "ARC defined stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Yonsei University", 
        "sponsors": {
            "collaborator": {
                "agency": "Gangwon Cardiovascular Health Research Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "3 Years", 
        "verification_date": "January 2014"
    }
}